Erratum: Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study (PLoS ONE (2014) 9:4 (e94928) DOI: 10.1371/journal.pone.0094928);Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Nolen, Brian M ^a   Brand, Randall E ^b   Prosser, Denise ^a   Velikokhatnaya, Liudmila ^a   Allen, Peter J ^c   Zeh, Herbert J ^a,b   Grizzle, William E ^d   Lomakin, Aleksey ^e   Lokshin, Anna E ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CHORIONIC GONADOTROPIN BETA SUBUNIT; COMPLEMENT COMPONENT C4; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 2; FOLLITROPIN; GROWTH HORMONE; INTERLEUKIN 8; NEURON SPECIFIC ENOLASE; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; PREALBUMIN; PROLACTIN; SCATTER FACTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; TUMOR MARKER;

ACINAR CELL CARCINOMA; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLLOID CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; BLOOD; MIDDLE AGED; PANCREATIC NEOPLASMS; PROCEDURES;

AGED; CA-19-9 ANTIGEN; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; OSTEOPROTEGERIN; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84899699064     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117876     Document Type: Erratum

References (60)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute Bethesda, MD.
2. Michaud DS (2004) Epidemiology of pancreatic cancer. Minerva Chir 59: 99-111.
3. Sohn TA, Lillemoe KD (2000) Surgical palliation of pancreatic cancer. Adv Surg 34: 249-271.
4. Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270. (Pubitemid 46488663)
5. Chen R, Crispin DA, Pan S, Hawley S, McIntosh MW, et al. (2010) Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas 39: 981-988.
6. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, et al. (2004) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13: 487-491. (Pubitemid 38737477)
7. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, et al. (2009) Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 38: 613-618.
8. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, et al. (2011) Serum biomarker panels for the detection of pancreatic cancer. Clinical Cancer Research 17: 805-816.
9. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, et al. (2013) Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 42: 193-197.
10. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, et al. (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5: e123.
11. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, et al. (2010) Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19: 2298-2306.
12. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, et al. (2007) Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16: 2101-2109. (Pubitemid 47621187)
13. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, et al. (2000) Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21: 273S-309S.
14. UPCI Luminex Core Facility. Available: http://www.upci.upmc.edu/luminex/ index.cfm.
15. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, et al. (2005) Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14: 981-987. (Pubitemid 40478567)
16. Benjamini Y, Hochberg Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological) 57: 289-300.
17. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, et al. (2010) Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28: 2159-2166.
18. Hawass NE (1997) Comparing the sensitivities and specificities of two diagnostic procedures performed on the same group of patients. Br J Radiol 70: 360-366.
19. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843. (Pubitemid 13033817)
20. Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, et al. (2012) ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One 7: e39018.
21. Schmiegel WH, Eberl W, Kreiker C, Kalthoff H, Butzow GH, et al. (1985) Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases. Hepatogastroenterology 32: 141-145. (Pubitemid 15015976)
22. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, et al. (2013) The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 13: 340-351.
23. Louhimo J, Alfthan H, Stenman UH, Haglund C (2004) Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 66: 126-131. (Pubitemid 38608379)
24. Dietel M, Arps H, Klapdor R, Muller-Hagen S, Sieck M, et al. (1986) Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera. J Cancer Res Clin Oncol 111: 257-265. (Pubitemid 16093087)
25. Ona FV, Zamcheck N, Dhar P, Moore T, Kupchik HZ (1973) Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324-327.
26. Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, et al. (2007) CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34: 436-443. (Pubitemid 46725785)
27. Strickland LA, Ross J, Williams S, Ross S, Romero M, et al. (2009) Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 218: 380-390.
28. Boeck S, Wittwer C, Heinemann V, Haas M, Kern C, et al. (2013) Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br J Cancer 108: 1684-1694.
29. O'Neal RL, Nam KT, LaFleur BJ, Barlow B, Nozaki K, et al. (2013) Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Hum Pathol 44: 734-742.
30. Chen J, Anderson M, Misek DE, Simeone DM, Lubman DM (2007) Characterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometry. J Chromatogr A 1162: 117-125. (Pubitemid 47187399)
31. Chen J, Wu W, Zhen C, Zhou H, Yang R, et al. (2013) Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer. Oncol Lett 6: 43-48.
32. Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M (2010) Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 24: 256-261.
33. Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, et al. (2013) Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol 139: 1117-1127.
34. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, et al. (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17: 805-816.
35. Syrigos KN, Fyssas I, Konstandoulakis MM, Harrington KJ, Papadopoulos S, et al. (1998) Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma. Gut 42: 88-91. (Pubitemid 28228393)
36. Kleeff J, Kothari NH, Friess H, Fan H, Korc M (2004) Adenovirus-mediated transfer of a truncated fibroblast growth factor (FGF) type I receptor blocks FGF-2 signaling in multiple pancreatic cancer cell lines. Pancreas 28: 25-30. (Pubitemid 38032241)
37. Xu D, Matsuo Y, Ma J, Koide S, Ochi N, et al. (2010) Cancer cell-derived IL-1alpha promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells. J Surg Oncol 102: 469-477.
38. El-Mesallamy HO, Hamdy NM, Zaghloul AS, Sallam AM (2013) Clinical value of circulating lipocalins and insulin-like growth factor axis in pancreatic cancer diagnosis. Pancreas 42: 149-154.
39. Kornmann M, Ishiwata T, Kleeff J, Beger HG, Korc M (2000) Fas and Fasligand expression in human pancreatic cancer. Ann Surg 231: 368-379. (Pubitemid 30137125)
40. Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, et al. (2002) Expression of clusterin in human pancreatic cancer. Pancreas 25: 234-238.
41. Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, et al. (2002) Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 21: 881-886.
42. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, et al. (2001) Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554. (Pubitemid 32783263)
43. Bloomston M, Shafii A, Zervos EE, Rojiani A, Rosemurgy AS (2002) MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer. J Surg Res 102: 35-38.
44. Kaur S, Chakraborty S, Baine MJ, Mallya K, Smith LM, et al. (2013) Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One 8: e55171.
45. Ben QW, Jin XL, Liu J, Cai X, Yuan F, et al. (2011) Periostin, a matrix specific protein, is associated with proliferation and invasion of pancreatic cancer. Oncol Rep 25: 709-716.
46. Park HD, Kang ES, Kim JW, Lee KT, Lee KH, et al. (2012) Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics 12: 3590-3597.
47. Ballehaninna UK, Chamberlain RS (2013) Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol.
48. Duraker N, Hot S, Polat Y, Hobek A, Gencler N, et al. (2007) CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95: 142-147. (Pubitemid 46238983)
49. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, et al. (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6: e1000046.
50. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, et al. (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34: 205-214. (Pubitemid 46294796)
51. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, et al. (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 107: 18545-18550.
52. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
53. Shin EJ, Canto MI (2012) Pancreatic cancer screening. Gastroenterol Clin North Am 41: 143-157.
54. Gonda TA, Lucas A, Saif MW (2011) Screening and detection of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP 12: 322-324.
55. Skates SJ (2012) Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer 22 Suppl 1: S24-26.
56. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST (2007) Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 102: 2157-2163. (Pubitemid 47493852)
57. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, et al. (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129: 504-511. (Pubitemid 41096638)
58. Damiano J, Bordier L, Le Berre JP, Margery J, Dupuy O, et al. (2004) Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab 30: 203-207. (Pubitemid 38715180)
59. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, et al. (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10: 2386-2392. (Pubitemid 38445697)
60. Tezel E, Kawase Y, Takeda S, Oshima K, Nakao A (2001) Expression of neural cell adhesion molecule in pancreatic cancer. Pancreas 22: 122-125. (Pubitemid 32179165)